According to Novartis's 2019 annual report, Novartis subsidiary Sandoz has discontinued development of a generic version of the Advair Diskus fluticasone propionate/salmeterol DPI for the treatment of asthma and COPD for the US market as of January 2020. In October 2016, Sandoz filed a citizen petition with the FDA asking that the agency delay approval of any … [Read more...] about Sandoz has discontinued its US generic Advair Diskus program
Business
Evoke announces commercialization deal with Eversana for Gimoti nasal spray
Days after announcing that the FDA has accepted its NDA resubmission for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis, Evoke Pharma said that the company has cancelled a previously announced commercialization deal with Novus Growth Partners and has signed a new 5-year deal with Eversana for commercialization and distribution of Gimoti … [Read more...] about Evoke announces commercialization deal with Eversana for Gimoti nasal spray
AstraZeneca announces plans for “next-generation inhaler” as part of “Ambition Zero Carbon” program
AstraZeneca has announced a commitment to launching a "next-generation" MDI with minimal global warming potential (GWP) propellants by 2025 as part of its $1 billion "Ambition Zero Carbon" program. The new program, which was announced at the World Economic Forum meeting in Davos, Switzerland, aims for zero carbon emissions by 2025 and a carbon negative value chain by … [Read more...] about AstraZeneca announces plans for “next-generation inhaler” as part of “Ambition Zero Carbon” program
Virpax to develop intranasal enkephalin formulation for the treatment of PTSD
Virpax Pharmaceuticals announced that it has acquired exclusive global rights from Nanomerics Ltd. for the use of molecular envelope technology (MET) for delivery of an intranasal formulation of enkephalin for the treatment of PTSD. The company says that PES200 will be delivered via a cartridge-based, pressurized nasal delivery device, presumably the Naltos dry … [Read more...] about Virpax to develop intranasal enkephalin formulation for the treatment of PTSD
Altavant Sciences acquires Onspira Therapeutics
Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101 for the treatment of bronchiolitis obliterans syndrome (BOS). According to Altavant, the deal included an upfront … [Read more...] about Altavant Sciences acquires Onspira Therapeutics
AI Therapeutics provides update on inhaled rapamycin
AI Therapeutics (formerly LAM Therapeutics) said that it is seeking a partner to advance its LAM-001 inhaled rapamycin into Phase 3 trials for the treatment of lymphangioleiomyomatosis (LAM disease) and into Phase 2 for the treatment of pulmonary arterial hypertension (PAH). The company said that LAM-001 has been granted Orphan Drug designation for LAM in Europe and … [Read more...] about AI Therapeutics provides update on inhaled rapamycin
Afrezza to be launched in Brazil
According to MannKind Corporation, Brazil's Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health Regulatory Agency (ANVISA) approved Afrezza for the treatment of diabetes in June 2019. In June 2017, MannKind announced that it … [Read more...] about Afrezza to be launched in Brazil
Impopharma acquired by Rubicon Research
Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma's Concord, ON facility will become Rubicon's Nasal and Pulmonary Center of Excellence. Impopharma's services included testing and development of nasal sprays, MDIs, and DPIs. According to Rubicon, the company expects the … [Read more...] about Impopharma acquired by Rubicon Research
Pulmatrix announces collaboration with Nocion Therapeutics
Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix's iSPERSE particle engineering technology for development of inhaled formulations of Nocion drugs. According to the Nocion web site, the company's lead candidate targets refractory chronic cough. … [Read more...] about Pulmatrix announces collaboration with Nocion Therapeutics
ATAI Life Sciences partners with Neuronasal on intranasal N-acetylcysteine for concussion
ATAI Life Sciences has announced a deal with US-based Neuronasal Inc. for development of intranasal N-acetylcysteine (NAC) for the treatment of mild traumatic brain injury (mTBI, or concussion). ATAI said that it expects initiation of a pilot study in healthy volunteers in February 2020. According to a Neuronasal presentation, the drug would be delivered via the … [Read more...] about ATAI Life Sciences partners with Neuronasal on intranasal N-acetylcysteine for concussion